These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29316072)

  • 1. The impact of patient age on breast cancer risk prediction models.
    Coopey SB; Acar A; Griffin M; Cintolo-Gonzalez J; Semine A; Hughes KS
    Breast J; 2018 Jul; 24(4):592-598. PubMed ID: 29316072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
    Fasching PA; Bani MR; Nestle-Krämling C; Goecke TO; Niederacher D; Beckmann MW; Lux MP
    Eur J Cancer Prev; 2007 Jun; 16(3):216-24. PubMed ID: 17415092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients.
    Kang E; Park SK; Yang JJ; Park B; Lee MH; Lee JW; Suh YJ; Lee JE; Kim HA; Oh SJ; Kim SW;
    Breast Cancer Res Treat; 2012 Aug; 134(3):1189-97. PubMed ID: 22438049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
    Hung FH; Wang YA; Jian JW; Peng HP; Hsieh LL; Hung CF; Yang MM; Yang AS
    Sci Rep; 2019 Jul; 9(1):10229. PubMed ID: 31308460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing BRCA carrier probabilities in extended families.
    Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
    J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Analysis between the Gail, Tyrer-Cuzick and BRCAPRO Models for Breast Cancer Screening in Brazilian Population.
    Stevanato KP; Pedroso RB; Iora P; Santos LD; Pelloso FC; Melo WA; Carvalho MDB; Pelloso SM
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3407-3413. PubMed ID: 31759366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of Estimated Lifetime Breast Cancer Risk Among Women Undergoing Screening Mammography.
    Niell BL; Augusto B; McIntyre M; Conley CC; Gerke T; Roetzheim R; Garcia J; Vadaparampil ST
    AJR Am J Roentgenol; 2021 Jul; 217(1):48-55. PubMed ID: 33978450
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.
    Amir E; Evans DG; Shenton A; Lalloo F; Moran A; Boggis C; Wilson M; Howell A
    J Med Genet; 2003 Nov; 40(11):807-14. PubMed ID: 14627668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alternative approach to selecting patients for high-risk screening with breast MRI.
    Hollingsworth AB; Stough RG
    Breast J; 2014; 20(2):192-7. PubMed ID: 24387050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.
    Murphy CD; Lee JM; Drohan B; Euhus DM; Kopans DB; Gadd MA; Rafferty EA; Specht MC; Smith BL; Hughes KS
    Cancer; 2008 Dec; 113(11):3116-20. PubMed ID: 18932252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk and risk assessment for breast cancer: molecular and clinical aspects.
    Beckmann MW; Bani MR; Fasching PA; Strick R; Lux MP
    Maturitas; 2007 May; 57(1):56-60. PubMed ID: 17386982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
    J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting a BRCA risk assessment model for use in a familial cancer clinic.
    Panchal SM; Ennis M; Canon S; Bordeleau LJ
    BMC Med Genet; 2008 Dec; 9():116. PubMed ID: 19102775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited family structure and BRCA gene mutation status in single cases of breast cancer.
    Weitzel JN; Lagos VI; Cullinane CA; Gambol PJ; Culver JO; Blazer KR; Palomares MR; Lowstuter KJ; MacDonald DJ
    JAMA; 2007 Jun; 297(23):2587-95. PubMed ID: 17579227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS.
    Valero MG; Zabor EC; Park A; Gilbert E; Newman A; King TA; Pilewskie ML
    Ann Surg Oncol; 2020 Mar; 27(3):736-740. PubMed ID: 31559544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Receiver Operating Characteristic (ROC) Curve Analysis for Tyrer-Cuzick and Gail in Breast Cancer Screening in Jiangxi Province, China.
    Zhang L; Jie Z; Xu S; Zhang L; Guo X
    Med Sci Monit; 2018 Aug; 24():5528-5532. PubMed ID: 30089770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
    J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.